KRAS Mutations in Squamous Cell Carcinomas of the Lung

KRAS is one of the most commonly mutated oncogenes in cancer, enabling tumor proliferation and maintenance. After various approaches to target KRAS have failed over the past decades, the first specific inhibitor of the p.G12C mutation of KRAS was recently approved by the FDA after showing promising...

Descripción completa

Detalles Bibliográficos
Autores principales: Acker, Fabian, Stratmann, Jan, Aspacher, Lukas, Nguyen, Ngoc Thien Thu, Wagner, Sebastian, Serve, Hubert, Wild, Peter J., Sebastian, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714661/
https://www.ncbi.nlm.nih.gov/pubmed/34976827
http://dx.doi.org/10.3389/fonc.2021.788084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714661/
https://www.ncbi.nlm.nih.gov/pubmed/34976827
http://dx.doi.org/10.3389/fonc.2021.788084

Ejemplares similares